XML 33 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
13. ACQUISITION/MERGER WITH SUBSIDIARIES
12 Months Ended
Aug. 31, 2017
Business Combinations [Abstract]  
ACQUISITION/MERGER WITH SUBSIDIARIES

Cognigen Corporation

 

On July 23, 2014, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Cognigen Corporation (“Cognigen”). On September 2, 2014, the Company consummated the acquisition of all outstanding equity interests of Cognigen pursuant to the terms of the Merger Agreement, with Cognigen merging with and into a newly formed, wholly owned subsidiary of the Company. We believe the combination of Simulations Plus and Cognigen provides substantial future potential based on the complementary strengths of each of the companies.

 

Under the terms of the Merger Agreement, as described below, the Company will pay the former shareholders of Cognigen total consideration of $7,000,000, consisting of $2,800,000 of cash and $4,200,000 worth of newly issued, unregistered shares of the Company’s common stock.

 

On September 2, 2014, the Company paid the former shareholders of Cognigen a total of $5,200,000, comprised of cash in the amount of $2,080,000 and the issuance of 491,159 shares of the Company’s common stock valued at $3,120,000 (under the terms of the Merger Agreement a price of approximately $6.35 dollars per share was used based upon the volume-weighted average closing price of the Company’s shares of common stock for the 30-consecutive-trading-day period ending two trading days prior to September 2, 2014). The actual stock price at September 2, 2014 was $6.67, so the total value of the stock issued was approximately $3,277,000. The Merger Agreement provides for a two-year market standoff period in which the newly issued shares may not be sold by the recipients thereof.

 

Within three business days following the two-year anniversary of July 23, 2014 (the date of the Merger Agreement) and subject to any offsets, the Company will pay the former shareholders of Cognigen a total of $1,800,000, comprised of $720,000 of cash and the issuance of 170,014 shares of stock valued at $1,080,000 under the formula described above.

 

The Merger Agreement provided for a targeted working capital adjustment to be made 120 days after the closing date.

 

Under the acquisition method of accounting, the total estimated purchase price is allocated to Cognigen’s tangible and intangible assets and liabilities based on their estimated fair values at the date of the completion of the acquisition (September 2, 2014). The following table summarizes the preliminary allocation of the purchase price for Cognigen:

 

Assets acquired, including accounts receivable of $934,000 and estimated Contracts receivable of $398,000   $ 1,524,389  
Fixed assets acquired     458,351  
Estimated value of software acquired     200,000  
Estimated value of Intangibles acquired (Customer Lists, trade name etc.)     1,600,000  
Working Capital Adjustment     (26,707 )
Current Liabilities assumed     (644,499 )
Goodwill     4,789,248  
Estimated Deferred income taxes     (662,500 )
         
Total Consideration   $ 7,238,282  

 

Goodwill has been provided in the transaction based on estimates of future earnings of this subsidiary including anticipated synergies associated with the positioning of the combined company as a leader in model-based drug development. Based on the structure of the transaction, the Company does not anticipate benefiting from any tax deductions in future periods for recognized goodwill.

 

DILIsym Services, Inc.

 

On May 1, 2017, the Company entered into an Stock Purchase Agreement (the “Stock Agreement”) with DILIsym Services, Inc (“DILIsym”). On June 1 2016, the Company consummated the acquisition of all outstanding equity interests of DILIsym pursuant to the terms of the Stock Agreement, with DILIsym becoming a wholly owned subsidiary of the Company. We believe the combination of Simulations Plus and DILIsym provides substantial future potential based on the complementary strengths of each of the companies.

 

Under the terms of the Stock Agreement, as described below, the Company will pay the former shareholders of DILIsym total consideration of approximately $10,463,000.

 

On June 1, 2017, the Company paid the former shareholders of DILIsym a total of $4,515,982, which included a $4,000,000 initial payment and a preliminary working capital payment of $515,982. Additional working capital adjustments of $247,328 are due under the agreement and will be paid subsequent to August 31, 2017.

 

Within three business days following the eighteen month anniversary of acquisition, May 1, 2017, (the date of the Stock Agreement) and subject to any offsets, the Company will pay the former shareholders of DILIsym a total of $1,000,000. The agreement calls for Earn-out payments up to an additional $5,000,000 based on a formula of pre-tax earnings over the next three years. The Earn-out liability has been recorded at fair value.

 

Under the acquisition method of accounting, the total estimated purchase price is allocated to DILIsym’s tangible and intangible assets and liabilities based on their estimated fair values at the date of the completion of the acquisition (June 1, 2017). The following table summarizes the preliminary allocation of the purchase price for DILIsym:

 

Assets acquired, including accounts receivable of $255,000 and estimated Contracts receivable of $153,000   $ 2,283,110  
Developed Technologies Acquired     2,850,000  
Estimated value of Intangibles acquired (Customer Lists, trade name etc.)     2,840,000  
Current Liabilities assumed     (911,049 )
Goodwill     5,597,950  
Estimated Deferred income taxes     (2,212,160 )
         
Total Consideration   $ 10,463,310  

 

Goodwill has been provided in the transaction based on estimates of future earnings of this subsidiary including anticipated synergies associated with the positioning of the combined company as a leader in model-based drug development. Based on the structure of the transaction, the Company does not anticipate benefiting from any tax deductions in future periods for recognized goodwill.

 

PROFORMA INFORMATION (UNAUDITED)

 

Consolidated supplemental Pro Forma information

 

The following consolidated supplemental pro forma information assumes that the acquisition of DILIsym took place on September 1, 2015 for the income statements for the fiscal year ended August 31, 2017, and 2016. These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of DILIsym to reflect the same expenses in the fiscal year ended August 31, 2017 that were incurred in the fiscal year ended August 31, 2016. The adjustments include costs of acquisition of $620,000, and the amortization of intangibles and other technologies acquired during the merger assuming the fair value adjustments applied on September 1, 2015, together with consequential tax effects.

 

    For the fiscal year ended
August 31
(in 1000’s)
 
    (Pro forma)*     (Pro forma)  
    2017     2016  
Net Sales   $ 27,184     $ 22,847  
Net Income   $ 6,325     $ 5,423  

 

*Includes 3 months actual results for the period of June 1, 2017 to August 31, 2017